Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Leqembi’s FSS Pricing Meets ICER’s Cost-Effectiveness Threshold; VA Requiring Coverage With Evidence

Mar 16 2023

• By Nielsen Hobbs

red white and blue brain — • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock image

Related Content

Eisai Plots A Meticulous Path To Medicare Coverage For Lecanemab

Dec 02 2022

ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High

Mar 01 2023

Eisai Pricing For Lecanemab Reflects Concern With Medicare ‘Sustainability,’ ‘Giving Back,’ Firm Says

Jan 07 2023

Leqembi Coverage By Veterans Affairs Department Sign Of Success For Eisai’s Payer Engagement Strategy

Mar 14 2023

Related Companies

Eisai Co., Ltd.

Biogen, Inc.

Additional Topics

United States Government Payers Pricing Strategies Policy Neurology BioPharmaceutical

More from Government Payers

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window